Cover Page - shares |
9 Months Ended | |
|---|---|---|
Aug. 31, 2024 |
Oct. 15, 2024 |
|
| Cover [Abstract] | ||
| Document Type | 10-Q/A | |
| Amendment Flag | true | |
| Document Period End Date | Aug. 31, 2024 | |
| Document Fiscal Year Focus | 2024 | |
| Document Fiscal Period Focus | Q3 | |
| Current Fiscal Year End Date | --11-30 | |
| Entity Interactive Data Current | Yes | |
| Entity Current Reporting Status | Yes | |
| Trading Symbol | CCEL | |
| Entity Central Index Key | 0000862692 | |
| Entity Registrant Name | CRYO-CELL INTERNATIONAL, INC. | |
| Entity Shell Company | false | |
| Entity Filer Category | Non-accelerated Filer | |
| Entity Small Business | true | |
| Entity Emerging Growth Company | false | |
| Entity File Number | 001-40767 | |
| Entity Incorporation, State or Country Code | DE | |
| Entity Tax Identification Number | 22-3023093 | |
| Entity Address, Address Line One | 700 Brooker Creek Blvd | |
| Entity Address, City or Town | Oldsmar | |
| Entity Address, State or Province | FL | |
| Entity Address, Postal Zip Code | 34677 | |
| City Area Code | 813 | |
| Local Phone Number | 749-2100 | |
| Document Quarterly Report | true | |
| Document Transition Report | false | |
| Title of 12(b) Security | Common Stock, $0.01 par value | |
| Entity Common Stock, Shares Outstanding | 8,062,159 | |
| Security Exchange Name | NYSEAMER | |
| Amendment Description | Explanatory Note This Amendment No. 1 (the “Amendment”) to the Quarterly Report on Form 10-Q of Cryo-Cell International, Inc. (the “Company”) for the third quarter ended August 31, 2024, originally filed with the Securities and Exchange Commission on October 15, 2024 (the “Original Form10-Q”), is being filed to amend and restate Part I – Financial Information (Unaudited), Item 1, Financial Statements, Notes to Consolidated Financial Statements, Note 9 - Commitments and Contingencies, Legal Proceedings, first paragraph, and Part II - Other Information, Item 1, Legal Proceedings, first paragraph, to include updated disclosure regarding the legal proceeding Lindsey Lehr v. Cryo-Cell International, Inc.. Those paragraphs are replaced with the following: On January 6, 2023, a complaint styled Lindsey Lehr v. Cryo-Cell International, Inc., Case No. 50-2023-CA-000091, was filed in the Circuit Court for Palm Beach County, Florida, naming the Company as defendant and asserting claims on behalf of a putative class of individuals who entered agreements with the Company for umbilical cord blood storage services since May 2018. The complaint alleged that the Company’s advertising does not accurately represent the value and efficacy of its services and asserted claims (and sought unspecified damages) under Florida law. On March 14, 2023, the Company removed the case to the United States District Court for the Southern District of Florida (Case No. 9:23-cv-80405-AMC), and on March 21, 2023, moved to compel arbitration and stay the case. On October 10, 2023, the Court granted the Company’s motion to compel arbitration and stayed the case. On October 27, 2023, the plaintiff filed a demand for arbitration and statement of claims with the American Arbitration Association, and on January 18, 2024, the plaintiff filed an amended statement of claims dropping her class action allegations against the Company. On March 19, 2024, the Company filed an answering statement and counterclaim in response to the plaintiff’s claims. The Company believes the plaintiff’s claims are unlikely to prevail and intends to contest the action vigorously. The Company believes that the resolution of this matter should not have a material adverse effect on the Company’s business, consolidated financial position or results of operations. It is possible, however, that there could be an unfavorable outcome or resolution of the claims asserted, which could negatively and materially impact the Company’s business, consolidated financial position and results of operations. Litigation is inherently uncertain and there can be no assurance that the Company will prevail. The Company does not include an estimate of legal fees and other related defense costs in its estimate of loss contingencies. This Amendment should be read in conjunction with the Original Form 10-Q, is limited in scope to the correction described above and does not amend, update, or change any other items or disclosures contained in the Original Form 10-Q. Accordingly, all other items that remain unaffected are omitted in this filing. Except as described in the preceding paragraph, this Amendment does not update any of the information contained in the Original Form 10-Q, which continues to speak as of the original filing date of the Original Form 10-Q. |